Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin widens to 6.4%
Net margin was 6.4% in Q1 FY2026, up 15.5 pp from a year earlier. On a trailing-twelve-month basis it was -1.7%, up 7.8 pp year over year. Over 3 fiscal years it widened by 36.7 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 3 analysts of 32.3% for the fiscal year ending Dec 2026, up from -5.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 6.4%-0.6 pp QoQ
- Last fiscal yearDec 2025
- -5.8%+4.0 pp YoY
- LTMMar 2026
- -1.7%+7.8 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.5 pp | +36.9 pp | +21.4 pp |
| 1 year | +4.0 pp | +38.1 pp | +34.0 pp |
| 3 years | +36.7 pp | +36.6 pp | -0.1 pp |
| 5 years | +41.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -5.8%
- Year-over-year change
- +4.0pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -5.8% | +4.0pp |
| FY2024 | 2024-12-31 | -9.8% | -6.8pp |
| FY2023 | 2023-12-31 | -3.0% | +39.5pp |
| FY2022 | 2022-12-31 | -42.4% | -33.5pp |
| FY2021 | 2021-12-31 | -9.0% | — |
Net Margin vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 net margin of -1.7% is the 3rd highest of the 8 companies compared; the peer median is -18.7%.
- Its year-over-year change of +7.8 pp is the 4th highest of 8, against a peer median of +7.7 pp.
- Over three fiscal years its change of +36.7 pp compares with a peer median of +249.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 101.6% | +328.2 pp | +341.6 pp | |
| LTM Mar 2026 | 3.3% | +7.7 pp | -5.9 pp | |
| LTM Mar 2026 | -1.7% | +7.8 pp | +36.7 pp | |
| LTM Mar 2026 | -16.4% | +30.3 pp | +1523.1 pp | |
| LTM Sep 2026 | -18.7% | +1.7 pp | +249.2 pp | |
| LTM Mar 2026 | -37.5% | +530.6 pp | +73239.9 pp | |
| LTM Sep 2026 | -56.9% | -30.4 pp | +5.6 pp | |
| LTM Mar 2026 | -91.0% | +2.0 pp | +109.3 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ETON) | -18.7% | +7.7 pp | +249.2 pp | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.83M | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | 2.62M | 6.93M | 10.58M | 15.6M | 37.21M |
| Gross Profit | 19.21M | 14.32M | 21.06M | 23.41M | 42.74M |
| Gross Margin | 88.0% | 67.4% | 66.6% | 60.0% | 53.5% |
| Research & Development | 6.24M | 4M | 3.32M | 3.26M | 7.77M |
| Selling, General & Admin | 14.47M | 18.58M | 18.93M | 22.75M | 35.82M |
| Operating Expenses | 20.7M | 22.58M | 22.25M | 26.01M | 42.67M |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| EBITDA | (1.49M) | (7.25M) | 212K | (657K) | 4.27M |
| EBITDA Margin | -6.8% | -34.1% | 0.7% | -1.7% | 5.3% |
| Operating Income | (1.5M) | (8.26M) | (1.19M) | (2.6M) | 72K |
| Operating Margin | -6.8% | -38.9% | -3.8% | -6.7% | 0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.04M | 955K | 1.06M | 2.01M | 4.78M |
| Other Income / Expenses | (460K) | (761K) | 503K | (1.21M) | (4.63M) |
| Income Before Tax | (1.96M) | (9.02M) | (689K) | (3.81M) | (4.56M) |
| Pre-Tax Margin | -9.0% | -42.4% | -2.2% | -9.8% | -5.7% |
| Income Tax Expense | 0 | 0 | 247K | 15K | 43K |
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Net Margin | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| EPS (Basic) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| EPS (Diluted) | (0.08) | (0.36) | (0.04) | (0.15) | (0.17) |
| Weighted Avg Shares | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
| Weighted Avg Shares (Diluted) | 25.21M | 25.15M | 25.65M | 25.9M | 26.91M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.